GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Henan Taloph Pharmaceutical Stock Co 600222.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

6.61

+2.01%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Henan Taloph Pharmaceutical Stock Co

Its shares trade on Shanghai under the ticker 600222.SS. It has been listed since 5 November 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.76bn and net income of CN¥60.0m. At that date it held total assets of CN¥3.64bn and shareholders' equity of CN¥1.60bn.

Henan Taloph Pharmaceutical Stock Co., Ltd. engages in the pharmaceutical manufacturing industry. The company is headquartered in Zhengzhou, Henan. The firm provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The firm's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The firm distributes its products mainly within domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
5 Nov 1999
Employees
2,658
Website
taloph.com ↗

Leadership

Pay as last reported

  • Mr. Hui YinChairman of the Board, since 2022
  • Mr. Jingliang LiVice Chairman of the Board, General Manager, since 2023CN¥1.1m
  • Mr. Hui LiVice Chairman of the Board, since 2022CN¥1.7m
  • Mr. Hailin ZhaoFinance Director, Executive Deputy General ManagerCN¥586,400
  • Mr. Jianchao LuoGeneral Manager, since 2005CN¥1.2m
  • Ms. Nianyun LiDeputy General Manager, Secretary of the Board
  • Mr. Fengshan SuDeputy General ManagerCN¥687,200
  • Mr. Lizhuang ZhangDeputy General ManagerCN¥575,500
  • Ms. Jinge ChenDirector
  • Mr. Siliang ChenDirector
  • Mr. Shiguang MaDirector
  • Mr. Liang FangIndependent DirectorCN¥38,600

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Henan Taloph Pharmaceutical employs 2,658 full-time staff in Zhengzhou, CN.
  • Shuanghuanglian oral liquid is a key product for treating colds and viral infections.
  • The company's main products include Haberffine tablets and compound Yimu oral solutions.

Weaknesses

  • The firm distributes products mainly within the domestic market of China.
  • Henan Taloph Pharmaceutical has no international presence or export markets.
  • The company's business is limited to domestic sales without global expansion.

Opportunities

  • The domestic market in China offers growth potential for pharmaceutical products.
  • Increasing demand for cold and diabetes treatments in Henan Province.
  • Expanding product lines could attract more customers in the Health Care sector.

Threats

  • Dependence on the domestic Chinese market for all sales revenue.
  • Competition from other domestic pharmaceutical companies in China.
  • Rising costs of raw materials may impact production efficiency.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.